Search clinical trials for: CAB-201 following preconditioning with fludarabine and cyclophosphamide

Total 317 results

Cabaletta Bio

Recruiting

RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy

Idiopathic Inflammatory Myopathy | Dermatomyositis | Immune-Mediated Necrotizing Myopathy | Anti-Synthetase Syndrome

United States
RenJi Hospital
Shanghai Simnova Biotechnology Co.,Ltd.

Recruiting

F01 in the Treatment of Autoimmune Diseases

Autoimmune Diseases

China
University College, London

Active, not recruiting

CARPALL: Immunotherapy With CD19/22 CAR T-cells for CD19+ Haematological Malignancies

Burkitt Lymphoma | Acute Lymphoblastic Leukemia

United Kingdom
Wuhan Union Hospital, China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Recruiting

Anti-FLT3 CAR-T Cell (TAA05 Cell Injection) in the Treatment of Relapsed / Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia

China
Second Affiliated Hospital, School of Medicine,...
Carbiogene Therapeutics Co. Ltd.

Recruiting

Novel BCMA-targeted CAR-T Cell Therapy for Multiple Myeloma

Relapsed or Refractory Multiple Myeloma

China
Hebei Senlang Biotechnology Inc., Ltd.
Hebei Medical University Fourth Hospital

Recruiting

Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Plasma Cell Tumors

Plasma Cell Tumors

China
Beijing Immunochina Medical Science & Technology...

Completed

Safety and Efficacy Evaluation of IM19 CAR-T Cells (IM19CAR-T)

Leukemia

China
Wuhan Union Hospital, China
Shanghai Simnova Biotechnology Co.,Ltd.

Recruiting

Cord Blood Derived Anti-CD19 CAR-Engineered NK Cells for B Lymphoid Malignancies

Chronic Lymphocytic Leukemia | Acute Lymphocytic Leukemia | Non Hodgkin's Lymphoma

China
Wuhan Union Hospital, China
Guangzhou Bio-gene Technology Co., Ltd

Recruiting

A Clinical Study to Evaluate the Safety and Efficacy of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Received Three or More Lines of Therapy

Multiple Myeloma

China
Wuhan Union Hospital, China
Chengdu USino Technology Biology Co., Ltd

Recruiting

Universal Chimeric Antigen Receptor-modified AT19 Cells for CD19+ Relapsed/Refractory Hematological Malignancies

B-cell Lymphoma | Acute Lymphoblastic Leukemia | Chronic Lymphoblastic Leukemia

China
Hebei Senlang Biotechnology Inc., Ltd.
Hebei Medical University Fourth Hospital

Recruiting

A Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Hodgkin's Lymphoma

Hodgkin's Lymphoma

China
Beijing Immunochina Medical Science & Technology...

Unknown

Safety and Efficacy Evaluation of IM19 CAR-T Cells (IM19CAR-T)

Leukemia

China
Hebei Senlang Biotechnology Inc., Ltd.
Hebei Medical University Fourth Hospital

Recruiting

Clinical Trial of CAR-T in the Treatment of Relapsed and Refractory Hematopoietic and Lymphoid Tissue Tumors in Children

Lymphoma | Leukemia

China
Chinese PLA General Hospital
Peking University; EdiGene Inc.

Recruiting

TRAC and Power3 Genes Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-NHL

Non Hodgkin's Lymphoma

China
China Medical University, China
Shanghai First Song Therapeutics Co., Ltd

Recruiting

A Clinical Study Evaluating the Safety and Efficacy of Anti-HER2-CAR-T Cells Injection in Patients With Solid Tumors

Solid Tumor

China
Fudan University

Recruiting

A Clinical Research About CD70-targeted CAR-NKT Cells Therapy Advanced Malignant Solid Tumors

Solid Tumor

China
Hebei Senlang Biotechnology Inc., Ltd.
Hebei Medical University Fourth Hospital

Recruiting

A Multicenter Clinical Study on the Safety and Efficacy of CAR-T in the Treatment of Relapsed / Refractory Non Hodgkin's Lymphoma

Non-hodgkin's Lymphoma

China
Chinese PLA General Hospital

Recruiting

Chidamide Bridging for CAR-T Therapy

Non Hodgkin's Lymphoma

China
EdiGene Inc.
The First Affiliated Hospital of Henan University of Science and Technology; Changping Laboratory

Recruiting

A Study to Evaluate the Safety and Efficacy of ATHENA CAR-T in Subjects With Systemic Lupus Erythematosus

Lupus Erythematosus, Systemic

China
Chinese PLA General Hospital

Recruiting

Allogenic CD19-targeting CAR-γδT Cell Therapy in r/r NHL

Non Hodgkin's Lymphoma

China
Fudan University

Recruiting

CD70-targeted CAR-NKT Cells(CGC729) Therapy in the Renal Cell Carcinoma

Renal Cell Carcinoma

China
China Medical University, China
Shanghai First Song Therapeutics Co., Ltd

Recruiting

An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti-CEA-CAR-T Cells Injection in Patients With CEA+ Locally Advanced and/or Metastatic Solid Tumors

Carcinoma

China
Chinese PLA General Hospital

Recruiting

TCR Reserved and Power3 Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma

Non-hodgkin Lymphoma

China
Letolab

Not yet recruiting

A Phase I Study of LTC004 Combin With FC in Patients With Advanced/Metastatic Malignancies Tumor

Adult Solid Tumor
Malaghan Institute of Medical Research
Wellington Zhaotai Therapies Limited (WZTL)

Recruiting

ENABLE (Engaging Toll-like Receptor Signalling for B-cell Lymphoma Chimeric Antigen Receptor Therapy) (ENABLE)

Mantle Cell Lymphoma (MCL) | Diffuse Large B-cell Lymphoma (DLBCL) | Follicular Lymphoma (FL) | Lymphomas Non-Hodgkin's B-Cell | Transformed Follicular Lymphoma (TFL) | Primary Mediastinal B-cell Lymphoma (PMBCL)

New Zealand
National Cancer Institute (NCI)

Recruiting

CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies

Lymphoma, Non-Hodgkin | Acute Lymphoblastic Leukemia | Acute Lymphocytic Leukemia | Acute Lymphoid Leukemia | B-Cell Leukemia | Leukemia, Lymphocytic, B Cell | B-Cell Lymphoma | B-All | B-NHL | B-Non Hodgkin Lymphoma | B-precursor ALL

United States
Fred Hutchinson Cancer Center
Mustang Bio

Recruiting

A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Chronic Lymphocytic... and other conditions

United States
Celyad Oncology SA

Active, not recruiting

Safety, Activity and Cell Kinetics of CYAD-211 in Patients With Relapsed or Refractory Multiple Myeloma (IMMUNICY-1)

Relapse/Refractory Multiple Myeloma

Belgium, United States
Medical University of South Carolina

Recruiting

Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL

Chronic Lymphocytic Leukemia | B-cell Non Hodgkin Lymphoma

United States
C. Babis Andreadis
University of California, Davis

Recruiting

Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma

Follicular Lymphoma | Burkitt Lymphoma | Mantle Cell Lymphoma | Lymphoplasmacytic Lymphoma | Diffuse Large B Cell Lymphoma | Refractory Non-Hodgkin Lymphoma | Small Lymphocytic Lymphoma | Primary Mediastinal Large B Cell Lymphoma | Transformed Lymphoma

United States
Hebei Senlang Biotechnology Inc., Ltd.
Hebei Yanda Ludaopei Hospital

Recruiting

Safety and Efficacy of CD19/CD22 Dual Targeted CAR-T Cell Therapy in R/R B-Cell Acute Lymphoblastic Leukemia

CD19+ and CD 22+ B-ALL

China
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Modified Immune Cells (TAG72-CAR T Cells) for the Treatment of Patients With Platinum Resistant Epithelial Ovarian Cancer

Platinum-Resistant Ovarian Carcinoma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Zhejiang University
Hangzhou Cheetah Cell Therapeutics Co., Ltd

Recruiting

BCMA CAR-NK For Patients With RRMM

Multiple Myeloma in Relapse | Multiple Myeloma, Refractory

China
Second Affiliated Hospital, School of Medicine,...

Recruiting

MESO-CAR T Cells Therapy for Relapsed and Refractory Epithelial Ovarian Cancer

Ovarian Cancer

China
Masonic Cancer Center, University of Minnesota

Active, not recruiting

MT2017-45: CAR-T Cell Therapy for Heme Malignancies

Acute Lymphoblastic Leukemia | Large B-cell Lymphoma

United States
GC Cell Corporation

Not yet recruiting

Phase 1 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-201

Breast Cancer | Gastric Cancer | Gastroesophageal Junction Adenocarcinoma

Australia
Artiva Biotherapeutics, Inc.

Not yet recruiting

A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors

Breast Cancer | Gastric Cancer | Gastroesophageal Junction Adenocarcinoma

Korea, Republic of, United States
Kyverna Therapeutics

Recruiting

A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis (KYSA-3)

Lupus Nephritis | Lupus Nephritis - WHO Class IV | Lupus Nephritis - WHO Class III

Germany
Kyverna Therapeutics

Recruiting

A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis

Lupus Nephritis | Lupus Nephritis - World Health Organization (WHO) Class III | Lupus Nephritis - WHO Class IV

United States
Masonic Cancer Center, University of Minnesota
National Heart, Lung, and Blood Institute (NHLBI)

Terminated

Donor Umbilical Cord Blood Transplant After Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Multiple Myeloma

United States
M.D. Anderson Cancer Center
Intrexon Corporation

Terminated

Study of Adoptive Cellular Therapy Using Autologous T Cells Transduced With Lentivirus to Express a CD33 Specific Chimeric Antigen Receptor in Patients With Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia

Acute Myeloid Leukemia | Hematopoietic/Lymphoid Cancer

United States
Beijing Sanbo Brain Hospital
Marino Biotechnology Co., Ltd.

Unknown

Pilot Study of Autologous Anti-EGFRvIII CAR T Cells in Recurrent Glioblastoma Multiforme

Glioblastoma Multiforme

China
Baylor College of Medicine
The Methodist Hospital Research Institute

Recruiting

CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30) (RELY-30)

Hodgkin's Lymphoma | Non-Hodgkin Lymphoma

United States
Sumithira Vasu
National Cancer Institute (NCI)

Recruiting

Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies

Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Refractory Chronic Lymphocytic Leukemia | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Recurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia | Recurrent High Grade... and other conditions

United States
Jonsson Comprehensive Cancer Center
Parker Institute for Cancer Immunotherapy

Recruiting

Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia

Recurrent Mantle Cell Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Chronic Lymphocytic Leukemia | CD20 Positive | Refractory Mantle Cell Lymphoma | Recurrent Chronic Lymphocytic Leukemia | Refractory... and other conditions

United States
Memorial Sloan Kettering Cancer Center
Boston Children's Hospital; Fred Hutchinson Cancer Center; Children's Hospital... and other collaborators

Completed

Hematopoietic Stem Cell Transplantation for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine

Leukemia | Myelodysplastic Syndrome | Aplastic Anemia

United States
Baylor College of Medicine
The Methodist Hospital Research Institute; Center for Cell and Gene Therapy...

Recruiting

Cell Therapy for High Risk T-Cell Malignancies Using CD7-Specific CAR Expressed On Autologous T Cells

T-cell Acute Lymphoblastic Lymphoma | T-non-Hodgkin Lymphoma

United States
Institute of Hematology & Blood Diseases Hospital
Hangzhou Qihan Biotech Co.,Ltd.

Not yet recruiting

Natural Killer(NK) Cell Therapy in Acute Myeloid Leukemia

Minimal Residual Disease | AML, Adult

China
Baylor College of Medicine
Center for Cell and Gene Therapy, Baylor College of Medicine

Recruiting

Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors

Liposarcoma | Liver Cancer | Rhabdomyosarcoma | Wilms Tumor | Malignant Rhabdoid Tumor | Yolk Sac Tumor

United States

Search clinical trials for: CAB-201 following preconditioning with fludarabine and cyclophosphamide

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Hong Kong

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations